ABOUT US
Our focus on glycogen synthase kinase-3β (the enzyme GSK-3β) has led to the development of the therapeutic candidate elraglusib (formerly known as 9-ING-41). Elraglusib has shown tremendous potential in the treatment of many different cancers when used alone or in combination with other types of cancer therapies, including chemotherapy and immune modulators such as checkpoint inhibitors. It is our belief that this versatile agent will improve clinical outcomes for patients suffering from advanced, hard-to-treat cancers.
LEADERSHIP
BOARD OF DIRECTORS
Scientific Advisory Board
TIMELINE
Take a look at the Actuate journey; where we’ve been, where we are, and where we are going. Click the button below to see our company’s history.
PARTNERING
As we continue to develop novel therapies to improve outcomes for patients. We are open to new partnerships with academic and scientific organizations.